GoldenGolden
Advanced Search
Jounce Therapeutics

Jounce Therapeutics

Jounce Therapeutics is an immunotherapy company developing therapies to cancer founded in 2013 by James P. Allison, Drew Pardoll, Louis M. Weiner, Padmanee Sharma, Robert D. Schreiber and Thomas F. Gajewski.

Jounce Therapeutics is a publicly funded, clinical-stage immunotherapy company based in Cambridge, Massachusetts that was founded in 2013 by Drew Pardoll, James P. Allison, Louis M. Weiner, Padmanee Sharma, Robert D. Schreiber, and Thomas F. Gajewski. The company is focused on the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits.

Products
JTX-2011

Jounce's lead product candidate is JTX-2011, a monoclonal antibody that binds to and activates the Inducible T-Cell Co-Stimulator (ICOS), a protein on the surface of certain T-cells that is believed will stimulate an immune response against a patient's cancer. It is intended to treat solid tumors as a single agent and in combination with other therapies. JTX-2011 is being evaluated in Phase 2 clinical trials.

JTX-8064

Another product candidate in Jounce's pipeline is JTX-8064. It is the company's lead Beyond T-cell program aimed at disrupting the interaction of targets on tumor-associated macrophages (TAMs) to skew the composition of macrophages within the tumor from immune-suppressing to immune-activating. Jounce is conducting IND enabling studies for this product.

JTX-4014

The third product in Jounce's pipeline is JTX-4014, another T-Cell targeting immunotherapy. The company filed its IND application in September 2018 and received approval to move to Phase 1 clinical trials in October 2018.

Partnerships
Celgene

In July 2016, Jounce entered into a collaboration with Celgene Corporation, which includes options to JTX-2011 and up to four early-stage programs to be selected from a defined pool of B cell, T regulatory cell, and tumor associated macrophage targets emerging from Jounce's Translational Science Platform and an additional option to equally share a checkpoint immuno-oncology program.

Funding
Series A

On February 14, 2013 Jounce Therapeutics completed their series A funding round with $47 million in funding from Third Rock Ventures.

Series B

On April 23, 2015 Jounce Therapeutics completed their series B funding round with $56 million in funding from Wellington Management, Redmile Group, Pharmstandard, Omega Funds, Nextech Invest, Inbio Ventures, Foresite Capital, Cormorant Asset Management, and Casdin Capital.

Timeline

April 23, 2015
Series B

On April 23, 2015 Jounce Therapeutics completed their series B funding round with $56 million in funding from Wellington Management, Redmile Group, Pharmstandard, Omega Funds, Nextech Invest, Inbio Ventures, Foresite Capital, Cormorant Asset Management, and Casdin Capital.

March 15, 2013
Series A funding round

On February 14, 2013 Jounce Therapeutics completed their series A funding round with $47 million in funding from Third Rock Ventures.

February 2013
Jounce Therapeutics raises a $47,000,000 series A round from Third Rock Ventures.
2012
Jounce Therapeutics was founded by Robert D. Schreiber, Drew Pardoll, James P. Allison, Louis M. Weiner, Padmanee Sharma and Thomas F. Gajewski.

Funding rounds

People

Further reading

Documentaries, videos and podcasts

Companies

News

Title
Author
Date
Publisher
Description
BioSpace
April 10, 2021
BioSpace
Translational analysis of patients that do not respond to PD-(L)1 inhibitors show high pretreatment intratumoral LILRB2 expression relative to an IFNγ gene signature
BioSpace
November 16, 2020
BioSpace
-Phase 1 INNATE trial will evaluate JTX-8064 as a monotherapy and in combination with Jounce's PD-1 inhibitor, JTX-4014 - - O n track to begin enrollment by year-end 2020 -
Amirah Al Idrus
November 3, 2020
FierceBiotech
Jounce Therapeutics and its lead prospect took a hit Monday as its stopped enrollment in a phase 2 lung cancer trial. The company was testing the drug alongside Bristol Myers Squibb's Yervoy in patients with non-small cell lung cancer, but an early look at the data showed the combo was unlikely to succeed.
Ben Adams
June 5, 2020
FierceBiotech
After culling a $2.6 billion biobucks pact last year, Bristol Myers Squibb is making a second and final cut to its pact with I-O biotech Jounce Therapeutics.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.